帕立骨化醇联合西那卡塞治疗甲状旁腺功能亢进临床观察

Clinical Observation of Paricalcitol Combined with Cinacalcet in the Treatment of Hyperparathyroidism

目的探讨帕立骨化醇联合西那卡塞治疗甲状旁腺功能亢进(简称甲旁亢)的临床疗效。方法选取医院2021年1月至2022年8月收治的甲旁亢患者70例,按随机信封法分为对照组和观察组,各35例。两组患者均予西那卡塞治疗,观察组加用帕立骨化醇,均连续治疗6个月。结果观察组总有效率为97.14%,显著高于对照组的74.29%(P<0.05);两组患者治疗后的疼痛程度评分、甲状旁腺体积、甲状旁腺激素水平均显著降低(P<0.05),且观察组均显著低于对照组(P<0.05);观察组与对照组治疗期间不良反应发生率相当(14.29%比2.86%,P>0.05)。结论帕立骨化醇联合西那卡塞治疗甲旁亢的临床疗效良好,能缓解患者的疼痛程度,缩小甲状旁腺体积,降低甲状旁腺激素水平,且安全性良好。

Objective To investigate the clinical efficacy of paricalcitol combined with cinacalcet in the treatment of hyperparathyroidism.Methods A total of 70 patients with hyperparathyroidism admitted to the hospital from January 2021 to August 2022 were selected and randomly divided into the control group and the observation group by the random envelope method,with 35 cases in each group.The patients in the two groups were treated with cinacalcet,while the patients in the observation group were treated with paricalcitol.Both groups were treated for six months.Results The total effective rate in the observation group was 97.14%,which was significantly higher than 74.29%in the control group(P<0.05).After treatment,the pain score,parathyroid volume,and parathyroid hormone levels in the two groups were significantly lower than those before treatment(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).During the treatment,the incidence of adverse reactions in the observation group was comparable to that in the control group(14.29%vs.2.86%,P>0.05).Conclusion Paricalcitol combined with cinacalcet is effective and safe in the treatment of hyperparathyroidism,which can alleviate the pain level of patients,and reduce the volume of parathyroid glands,and parathyroid hormone levels.